Avid Bioservices Inc (CDMO)

[entdoc]

ahamdrummond, agreed that irradiation + Bavi, and preop or post op irradiation + Bavi presents problems with measuring outcomes over long periods of survival time, but do not agree that it would be a hard sell to enroll patients. It is definitely easier to measure outcomes in hopeless cases with short survival times being treated with chemotherapy, but that is not the optimal indication for Bavi use. A surgeon or radiation therapy would jump at the obvious opportunity to improve his survival statistics with an agent like Bavi. Now we are testing Bavi in end-stage disease, disease in which there is no realistic expectation of cure, and expecting unrealistic reversals of disease. What we should be expecting is a good safety profile and indications of anticancer/pro-immunostimulatory effects, and that is what we have.
Patients treated with surgery usually have a shot at long-term survival or cure, and similar with irradiation and/or surgery. If not, they are given chemotherapy.
Addition of Bavi to irradiation or surgery protocols would expand the indications for either therapy.
That is, in cancer cases in which metastases are already present, surgery is often not offered now, but with Bavi to control metastases more surgery can be performed to control the primary cancers. By expanding the indications for surgery or irradiation we expand survivability and expand the stage of cancer that can be cured.